Silexion Therapeutics Corp filed Amendment No. 1 to its annual report for the year ended December 31, 2025. The amendment is narrowly focused on correcting typographical errors in Item 9A so that the date of management’s evaluation of internal control over financial reporting is properly stated as December 31, 2025 rather than December 31, 2024.
Management, including the Chief Executive Officer and Chief Financial Officer, evaluated disclosure controls and procedures and internal control over financial reporting as of December 31, 2025 using the COSO 2013 framework and concluded both were effective. As a non-accelerated, emerging growth company, Silexion is not required to obtain an auditor attestation on internal control.
The company states there were no changes in internal control over financial reporting during the three-month period ended December 31, 2025 that materially affected, or are reasonably likely to materially affect, these controls. Other disclosures from the original Form 10-K remain unchanged, aside from updated exhibits and certifications. As of June 30, 2025, non-affiliate ordinary shares had an aggregate market value of $6,619,600, and 3,330,785 ordinary shares were outstanding as of March 10, 2026.
Silexion Therapeutics Corp filed Amendment No. 1 to its annual report for the year ended December 31, 2025. The amendment is narrowly focused on correcting typographical errors in Item 9A so that the date of management’s evaluation of internal control over financial reporting is properly stated as December 31, 2025 rather than December 31, 2024.
Management, including the Chief Executive Officer and Chief Financial Officer, evaluated disclosure controls and procedures and internal control over financial reporting as of December 31, 2025 using the COSO 2013 framework and concluded both were effective. As a non-accelerated, emerging growth company, Silexion is not required to obtain an auditor attestation on internal control.
The company states there were no changes in internal control over financial reporting during the three-month period ended December 31, 2025 that materially affected, or are reasonably likely to materially affect, these controls. Other disclosures from the original Form 10-K remain unchanged, aside from updated exhibits and certifications. As of June 30, 2025, non-affiliate ordinary shares had an aggregate market value of $6,619,600, and 3,330,785 ordinary shares were outstanding as of March 10, 2026.
Silexion Therapeutics reported first quarter 2026 results and highlighted progress for its lead RNAi candidate SIL204 in locally advanced pancreatic cancer. The Israeli Ministry of Health approved initiation of a Phase 2/3 clinical trial, and a Clinical Trial Application was submitted in Germany under the EU Clinical Trials Regulation, keeping trial initiation on track for the second quarter of 2026.
For the three months ended March 31, 2026, Silexion recorded a net loss of $2.7 million compared with $1.7 million a year earlier, driven by higher research and development expense of $1.4 million and general and administrative expense of $1.4 million. Cash and cash equivalents declined to $2.4 million from $6.0 million as of December 31, 2025, while shareholders’ equity fell to $0.3 million from $2.6 million, and a related party promissory note of $1.6 million was reclassified into current liabilities. Management noted warrant exercise inducements, at-the-market usage and shareholder approval for a prospective reverse share split as steps to support both clinical development and continued Nasdaq listing.
Silexion Therapeutics reported first quarter 2026 results and highlighted progress for its lead RNAi candidate SIL204 in locally advanced pancreatic cancer. The Israeli Ministry of Health approved initiation of a Phase 2/3 clinical trial, and a Clinical Trial Application was submitted in Germany under the EU Clinical Trials Regulation, keeping trial initiation on track for the second quarter of 2026.
For the three months ended March 31, 2026, Silexion recorded a net loss of $2.7 million compared with $1.7 million a year earlier, driven by higher research and development expense of $1.4 million and general and administrative expense of $1.4 million. Cash and cash equivalents declined to $2.4 million from $6.0 million as of December 31, 2025, while shareholders’ equity fell to $0.3 million from $2.6 million, and a related party promissory note of $1.6 million was reclassified into current liabilities. Management noted warrant exercise inducements, at-the-market usage and shareholder approval for a prospective reverse share split as steps to support both clinical development and continued Nasdaq listing.
Silexion Therapeutics Corp reports a wider net loss as it funds its KRAS-targeted RNAi cancer pipeline. For the three months ended March 31, 2026, net loss rose to $2.7M from $1.7M a year earlier, driven by higher research and development spending of $1.4M versus $0.6M, mainly for toxicology work, product development and trial preparation. General and administrative expenses increased to $1.4M from $1.1M, reflecting professional services and share-based compensation for directors and executives.
Cash and cash equivalents fell to $2.4M at March 31, 2026 from $6.0M at December 31, 2025, with operating activities using $3.6M of cash in the quarter. Shareholders’ equity declined sharply to $0.3M from $2.6M, prompting management to conclude there is substantial doubt about the company’s ability to continue as a going concern.
To bolster liquidity, Silexion raised modest funds under an at-the-market facility in the quarter and, after quarter-end, completed a large warrant exercise inducement and additional ATM sales, and increased its authorized share capital. Shareholders also approved a 1-for-10 reverse share split intended to support continued Nasdaq listing and future capital-raising.
Silexion Therapeutics Corp reports a wider net loss as it funds its KRAS-targeted RNAi cancer pipeline. For the three months ended March 31, 2026, net loss rose to $2.7M from $1.7M a year earlier, driven by higher research and development spending of $1.4M versus $0.6M, mainly for toxicology work, product development and trial preparation. General and administrative expenses increased to $1.4M from $1.1M, reflecting professional services and share-based compensation for directors and executives.
Cash and cash equivalents fell to $2.4M at March 31, 2026 from $6.0M at December 31, 2025, with operating activities using $3.6M of cash in the quarter. Shareholders’ equity declined sharply to $0.3M from $2.6M, prompting management to conclude there is substantial doubt about the company’s ability to continue as a going concern.
To bolster liquidity, Silexion raised modest funds under an at-the-market facility in the quarter and, after quarter-end, completed a large warrant exercise inducement and additional ATM sales, and increased its authorized share capital. Shareholders also approved a 1-for-10 reverse share split intended to support continued Nasdaq listing and future capital-raising.
Silexion Therapeutics Corp entered into an inducement agreement with holders of 1,995,092 existing warrants to exercise them for cash at a reduced price of $0.50 per share, in exchange for 3,990,184 new warrants at the same exercise price. The company expects about $1.0 million in gross proceeds before fees, which it plans to use for general corporate purposes. New Series C and Series D warrants become exercisable only after shareholder approval and effectiveness of a resale registration statement and include 4.99% or 9.99% ownership limits, cashless exercise mechanics and five-year or 24‑month terms.
Silexion Therapeutics Corp entered into an inducement agreement with holders of 1,995,092 existing warrants to exercise them for cash at a reduced price of $0.50 per share, in exchange for 3,990,184 new warrants at the same exercise price. The company expects about $1.0 million in gross proceeds before fees, which it plans to use for general corporate purposes. New Series C and Series D warrants become exercisable only after shareholder approval and effectiveness of a resale registration statement and include 4.99% or 9.99% ownership limits, cashless exercise mechanics and five-year or 24‑month terms.
Silexion Therapeutics Corp Schedule 13G/A amendment: Lind Global-related entities report beneficial ownership of 212,500 securities, representing 4.96% of the class. The holdings consist of 106,250 Series A-1 Warrants and 106,250 Series A-2 Warrants, each subject to an exercise limitation that prevents exercise if such exercise would raise beneficial ownership above 9.9%. The filing lists Lind Global Fund III LP, Lind Global Partners III LLC and Jeff Easton as reporting persons and shows sole voting and dispositive power for 212,500 instruments.
Silexion Therapeutics Corp Schedule 13G/A amendment: Lind Global-related entities report beneficial ownership of 212,500 securities, representing 4.96% of the class. The holdings consist of 106,250 Series A-1 Warrants and 106,250 Series A-2 Warrants, each subject to an exercise limitation that prevents exercise if such exercise would raise beneficial ownership above 9.9%. The filing lists Lind Global Fund III LP, Lind Global Partners III LLC and Jeff Easton as reporting persons and shows sole voting and dispositive power for 212,500 instruments.
Silexion Therapeutics reported early laboratory findings suggesting its lead RNAi candidate SIL204 may have an immune-modulating effect in KRAS-driven cancers. In a preclinical study using human pancreatic cancer cells with a KRAS G12R mutation, SIL204 treatment led to a statistically significant increase in MHC-I (HLA-ABC) expression, a key signal that helps cytotoxic T cells recognize tumor cells. The company notes this could support future evaluation of SIL204 in combination with anti-PD-1 immunotherapies such as pembrolizumab, although these results remain preliminary and preclinical. Silexion is advancing SIL204 towards clinical trials in Israel and the European Union for locally advanced pancreatic cancer.
Silexion Therapeutics reported early laboratory findings suggesting its lead RNAi candidate SIL204 may have an immune-modulating effect in KRAS-driven cancers. In a preclinical study using human pancreatic cancer cells with a KRAS G12R mutation, SIL204 treatment led to a statistically significant increase in MHC-I (HLA-ABC) expression, a key signal that helps cytotoxic T cells recognize tumor cells. The company notes this could support future evaluation of SIL204 in combination with anti-PD-1 immunotherapies such as pembrolizumab, although these results remain preliminary and preclinical. Silexion is advancing SIL204 towards clinical trials in Israel and the European Union for locally advanced pancreatic cancer.
Silexion Therapeutics Corp is advancing its lead RNAi cancer drug SIL204 by starting Good Manufacturing Practice (GMP) clinical batch manufacturing with Catalent at its Limoges, France facility. These clinical batches will be used as investigational medicinal product for the safety run-in segment of a planned Phase 2/3 trial in locally advanced pancreatic cancer.
The company also received approval from the Helsinki Ethics Committee of Tel Aviv Sourasky Medical Center for the planned Phase 2/3 study at this leading Israeli oncology site, following prior authorization from the Israeli Ministry of Health and a Clinical Trial Application submission in Germany. Together, the manufacturing progress and multi-country regulatory steps move SIL204 closer to first patient dosing in a Phase 2/3 trial combining SIL204 with standard chemotherapy and using a dual-route (intratumoral and systemic) administration strategy.
Silexion Therapeutics Corp is advancing its lead RNAi cancer drug SIL204 by starting Good Manufacturing Practice (GMP) clinical batch manufacturing with Catalent at its Limoges, France facility. These clinical batches will be used as investigational medicinal product for the safety run-in segment of a planned Phase 2/3 trial in locally advanced pancreatic cancer.
The company also received approval from the Helsinki Ethics Committee of Tel Aviv Sourasky Medical Center for the planned Phase 2/3 study at this leading Israeli oncology site, following prior authorization from the Israeli Ministry of Health and a Clinical Trial Application submission in Germany. Together, the manufacturing progress and multi-country regulatory steps move SIL204 closer to first patient dosing in a Phase 2/3 trial combining SIL204 with standard chemotherapy and using a dual-route (intratumoral and systemic) administration strategy.
Silexion Therapeutics Corp held a reconvened extraordinary general meeting on May 5, 2026, where shareholders approved several capital structure changes. The key step was a Memorandum Amendment increasing authorized share capital from US$121,500, divided into 9,000,000 ordinary shares, to US$796,500, divided into 59,000,000 ordinary shares, each with a par value of US$0.0135. Shareholders also approved an evergreen increase and a reverse share split proposal. The meeting proceeded after 1,638,079 ordinary shares, representing about 40.2% of issued and outstanding shares, constituted a quorum under the company’s articles. Each proposal received around 61% of votes cast in favor, meeting the simple majority threshold.
Silexion Therapeutics Corp held a reconvened extraordinary general meeting on May 5, 2026, where shareholders approved several capital structure changes. The key step was a Memorandum Amendment increasing authorized share capital from US$121,500, divided into 9,000,000 ordinary shares, to US$796,500, divided into 59,000,000 ordinary shares, each with a par value of US$0.0135. Shareholders also approved an evergreen increase and a reverse share split proposal. The meeting proceeded after 1,638,079 ordinary shares, representing about 40.2% of issued and outstanding shares, constituted a quorum under the company’s articles. Each proposal received around 61% of votes cast in favor, meeting the simple majority threshold.
Silexion Therapeutics Corp furnished an update that it has successfully submitted a Clinical Trial Application in Germany for a planned Phase 2/3 trial of its lead siRNA therapy, SIL204, in KRAS-driven locally advanced pancreatic cancer. Germany will act as the Reporting Member State for the European Union review under the CTIS system, following earlier approval from the Israeli Ministry of Health for the same Phase 2/3 trial. The company plans to start the global Phase 2/3 study in the second quarter of 2026, combining intratumoral and systemic administration of SIL204 with standard chemotherapy at leading oncology centers in Germany, other EU states and Israel.
Silexion Therapeutics Corp furnished an update that it has successfully submitted a Clinical Trial Application in Germany for a planned Phase 2/3 trial of its lead siRNA therapy, SIL204, in KRAS-driven locally advanced pancreatic cancer. Germany will act as the Reporting Member State for the European Union review under the CTIS system, following earlier approval from the Israeli Ministry of Health for the same Phase 2/3 trial. The company plans to start the global Phase 2/3 study in the second quarter of 2026, combining intratumoral and systemic administration of SIL204 with standard chemotherapy at leading oncology centers in Germany, other EU states and Israel.
Silexion Therapeutics Corp is asking shareholders to approve three major capital-structure changes at an extraordinary general meeting on April 28, 2026. The board wants to increase authorized share capital from 9,000,000 to 59,000,000 ordinary shares, citing a lack of unissued shares and the need to maintain at least $2.5 million of shareholders’ equity required by Nasdaq.
A second proposal would amend the 2024 Equity Incentive Plan’s evergreen provision so that, each January 1, the pool reserved under all equity plans equals 10% of issued and outstanding shares on a fully diluted basis, up from a 5% of outstanding-shares formula. The third proposal authorizes a reverse share split of all ordinary shares, at a ratio between 1‑for‑4 and 1‑for‑10, to help keep the Nasdaq bid price above $1.00 and avoid potential delisting, without changing each holder’s percentage ownership aside from minor rounding of fractional shares.
Silexion Therapeutics Corp is asking shareholders to approve three major capital-structure changes at an extraordinary general meeting on April 28, 2026. The board wants to increase authorized share capital from 9,000,000 to 59,000,000 ordinary shares, citing a lack of unissued shares and the need to maintain at least $2.5 million of shareholders’ equity required by Nasdaq.
A second proposal would amend the 2024 Equity Incentive Plan’s evergreen provision so that, each January 1, the pool reserved under all equity plans equals 10% of issued and outstanding shares on a fully diluted basis, up from a 5% of outstanding-shares formula. The third proposal authorizes a reverse share split of all ordinary shares, at a ratio between 1‑for‑4 and 1‑for‑10, to help keep the Nasdaq bid price above $1.00 and avoid potential delisting, without changing each holder’s percentage ownership aside from minor rounding of fractional shares.